Literature DB >> 1782058

New anthracycline derivatives: what for?

K Mross1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1782058     DOI： 10.1016/0277-5379(91)90409-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  4 in total

Review 1.  A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.

Authors:  R Abraham; R L Basser; M D Green
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

Review 2.  Anthracyclines in the treatment of cancer. An overview.

Authors:  G N Hortobágyi
Journal:  Drugs       Date:  1997       Impact factor: 9.546

3.  Iododoxorubicin in advanced breast cancer: a phase II evaluation of clinical activity, pharmacology and quality of life.

Authors:  C J Twelves; N A Dobbs; M A Lawrence; A J Ramirez; M Summerhayes; M A Richards; K E Towlson; R D Rubens
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

4.  The Efficacy of Amifostine against Multiple-Dose Doxorubicin-Induced Toxicity in Rats.

Authors:  Vesna Jaćević; Viktorija Dragojević-Simić; Željka Tatomirović; Silva Dobrić; Dubravko Bokonjić; Aleksandra Kovačević; Eugenie Nepovimova; Martin Vališ; Kamil Kuča
Journal:  Int J Mol Sci       Date:  2018-08-12       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.